8-K ·Filed May 22, 2026

MAZE

Maze Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001193125-26-237199
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine senior finance departure with no red flags. The CFO absorbing accounting officer duties suggests no immediate disruption. Monitor for any future 8-K filings regarding a permanent replacement or any unexpected financial reporting changes.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
MAZE ▲ +12.90% at T+60d
NEUTRAL call ✓ call won +12.90% · α vs SPY +10.18% · entry $26.35 → $29.75
Entry anchored
May 22, 2026
via day open
T+1d
-1.14%
call -1.14% · α -1.15%
$26.05
settled 4mo ago
T+5d
-7.82%
call -7.82% · α -9.03%
$24.29
settled 4mo ago
T+20d
+1.40%
call +1.40% · α +3.35%
$26.72
settled 3mo ago
T+60d
+12.90%
call +12.90% · α +10.18%
$29.75
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Maze Therapeutics disclosed the resignation of Amy Bachrodt, Senior Vice President of Finance, effective June 1, 2026. The resignation is not related to any disagreement with the company's operations, policies, or financial reporting. CFO Misbah Tahir will assume the role of principal accounting officer following her departure.

Key Facts

  • Amy Bachrodt, SVP of Finance, resigned effective June 1, 2026.
  • Resignation not due to any disagreement with company operations, policies, or financial reporting.
  • CFO Misbah Tahir will be designated principal accounting officer post-departure.
  • No replacement named for the SVP of Finance role.

Financial Impact

No material financial impact disclosed.

Risk Factors

  • Potential temporary gap in finance leadership if CFO is overburdened.
  • No permanent replacement named could signal difficulty in attracting talent.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-237199
Document: 0001193125-26-237199-index-headers.html0001193125-26-237199
Document: 0001193125-26-237199-index.html0001193125-26-237199
Document: 0001193125-26-237199.txt0001193125-26-237199
19 reports for MAZE
Performance horizon
33% Hit rate 1 of 3 directional calls best @ T+5▲ +5.16%Jun 3, 2026
Filters
Rows
Reports for MAZE — sortable, filterable
TypeNow
Sep 4, 2026
27d ago
Insider Cluster
NEUTRAL ★ 2/10
$26.37 $24.23▼ −8.12%▼ −7.00%$26.69 (+1.20%)
Sep 4, 2026
27d ago
Insider Cluster
NEUTRAL ★ 3/10
$26.37 $24.23▼ −8.12%▼ −7.00%$26.69 (+1.20%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$25.87 $24.60▼ −4.91%▼ −3.76%$26.69 (+3.16%)
Sep 2, 2026
29d ago
144
NEUTRAL ★ 2/10
$25.87 $24.60▼ −4.91%▼ −3.76%$26.69 (+3.16%)
Sep 1, 2026
4w ago
144
NEUTRAL ★ 3/10
$26.72 $24.82▼ −7.11%▼ −6.15%$26.69 (−0.12%)
Aug 17, 2026
6w ago
3
NEUTRAL ★ 1/10
$29.13 $30.42▲ +4.43%▲ +4.63%$26.69 (−8.38%)
Aug 11, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$27.53 $29.75▲ +8.06%▲ +8.51%$26.69 (−3.06%)
Aug 7, 2026
8w ago
Institutional Cluster
BULLISH ★ 5/10
$28.65 $27.18▼ −5.13%▼ −5.53%$26.69 (−6.85%)
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.81 $27.53▼ −1.01%▼ −1.36%$26.69 (−4.04%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$31.26 $32.42▲ +3.71%▲ +2.78%$26.69 (−14.63%)
Showing 10 of 19

US Market Status

Market Open — Closes in 3h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access